Common Stock, $0.0001 par value per share
- Symbol
- TENX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Tenax Therapeutics, Inc.
TENXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 31, 2026, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.…
Press release in this filing
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update →Company context
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by SPHERA FUNDS MANAGEMENT LTD. regarding TENAX THERAPEUTICS, INC.Oct 13, 2026
- Other EventsOct 8, 2026
- SCHEDULE 13G/A - filed by ING GROEP NV regarding TENAX THERAPEUTICS, INC.Sep 11, 2026
- Regulation FD DisclosureSep 9, 2026
- SCHEDULE 13G - filed by ADAR1 Capital Management, LLC regarding TENAX THERAPEUTICS, INC.Sep 8, 2026
Registered securities in this filing
Tenax Therapeutics, Inc. · 8-K · Filed 2026-07-31
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On July 31, 2026, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 d90330dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) - Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress. “We are approaching an exciting moment, one for which we have been preparing since we began developing a therapy uniquely suited for PH-HFpEF. As we announced at the start of July, we expect to have topline data from the LEVEL clinical trial in August,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “In parallel, our team continues to activate sites and advance enrollment in LEVEL-2, our second global pivotal trial. We expect to complete LEVEL-2 enrollment by the end of 2027. Thank you to the entire team at Tenax for their commitment and dedication to rapidly advancing TNX-103 for patients.” Recent Corporate and Clinical Highlights In July 2026,…
Open exhibit ↗